S. aureus is the primary pathogen responsible for skin infections. They also reside in nasal passages and can be transferred to surgical wounds by self-inoculation. Mupirocin is the first-line topical antibacterial agent used for treating skin infections and nasal decolonization. Its introduction since 1985 has led to the emergence of mupirocin-resistant S. aureus. Indeed, a survey by seven public-sector hospitals in Singapore revealed 31% of clinical isolates were mupirocin-resistant, highlighting the need for a new antibacterial agent. I shall present ETC-670, a tetrapeptide bacterial membrane disruptor currently in pre-clinical development in Singapore as a replacement for mupirocin.